Segment Reporting
We have one operating segment and one reportable segment as our CODM, assesses the performance of our operations, develops strategy and reviews financial information on a consolidated basis for purposes of evaluating financial performance and allocating resources. The performance measure closest to U.S. GAAP used by our CODM to evaluate the performance of the Company’s ongoing operations on a consolidated basis and as part of the Company’s internal planning and forecasting activities is net loss attributable to common shareholders of Evolent Health, Inc. The CODM does not evaluate performance or allocate resources based on segment assets, and therefore such information is not presented in the notes to the financial statements.
The following table presents our revenue and significant expenses reviewed by our CODM, other segment items and net loss attributable to common shareholders of Evolent Health, Inc. (in thousands):
For the Year Ended December 31,
202520242023
Revenue$1,876,229 $2,554,741 $1,963,896 
Less:
Medical expense and device costs (1)
1,096,794 1,813,052 1,143,499 
Cost of revenue excluding medical expense and device costs and other segment items (2)
376,321 369,754 358,265 
Selling, general and administrative expenses excluding other segment items (3)
251,959 211,475 267,454 
Depreciation and amortization expenses115,851 118,370 123,415 
Goodwill impairment 398,000 — — 
Interest income(4,190)(5,544)(5,256)
Interest expense57,471 24,722 54,205 
Gain (loss) from equity method investees(365)3,441 (1,290)
Provision from income taxes(126)(1,413)(89,365)
Change in tax receivables agreement liability804 173 61,982 
Other segment items (4)
163,111 114,165 193,247 
Net loss attributable to common shareholders of Evolent Health, Inc.$(579,401)$(93,454)$(142,260)
————————
(1)Medical expenses and device costs include $907.3 million, $1.5 billion and $891.1 million of total claims incurred related to our specialty care management services solution for the years ended December 31, 2025, 2024 and 2023, respectively.
(2)Other segment items excluded from cost of revenue excluding medical expense and device costs include $3.2 million, $4.6 million and $1.7 million of stock compensation for the years ended December 31, 2025, 2024 and 2023, respectively.
(3)Other segment items excluded from selling, general and administrative expenses include the following (in thousands):

For the Year Ended December 31,
202520242023
Stock-based compensation$36,508 $35,164 $38,839 
Severance costs10,147 2,877 1,505 
Transaction-related costs5,252 2,934 15,076 
Repositioning costs— 10,600 35,236 
(4)Other segment items is defined as stock-based compensation, severance costs, transaction-related costs and repositioning costs not included in cost of revenue or selling, general and administrative expenses calculated in accordance with GAAP, loss on lease termination, (gain) loss on disposal of non-strategic assets, right-of-use assets impairment, change in fair value of contingent consideration, loss (gain) on extinguishment/repayment debt, loss on option exercise, extinguishment of Series A Preferred Stock and other refinancing fees, other income (expense), net, and dividends and accretion of Series A Preferred Stock and excise tax on Series A Preferred Stock. Management believes cost of revenue excluding medical expense and device costs and other segment items and selling, general and administrative expenses excluding other segment items are useful to investors because they facilitate an understanding of our long-term operational costs while removing the effect of costs that are not a representative component of the day-to-day operating performance of our business, and are useful to management as supplemental performance measures.

Historical Timeline

Fiscal YearFiled
2025Feb 25, 2026Showing above
2024Feb 21, 2025
2022Feb 24, 2023
2021Feb 24, 2022
2020Feb 26, 2021
2019Mar 2, 2020
2018Feb 28, 2019

About Segments Disclosures

Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.

Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.